| Background:Bladder cancer（BC）is one of the most common malignancies of the urinary system,while bladder urothelial carcinoma（UCB）is the most common histological subtype of BC.In recent years,despite rapid progress in the diagnosis and treatment of BC,the mortality rate remains high,and BC patients are prone to recurrence or metastasis after surgery.Currently,Bladder cancer lacks effective therapeutic targets and postoperative evaluation indicators.TTPE2（TNFAIP8L2）is a cytoplasmic protein composed of 184 amino acids,which was initially identified as a negative regulator of inflammation and immune system.Subsequent studies have found that TTPE2 is also involved in multiple signaling pathways of tumorigenesis and development,and plays a key role in different processes of cancer cell survival,proliferation,migration and invasion.Among different cancer types,TIPE2 expression level was decreased in liver cancer,breast cancer,stomach cancer,esophageal cancer and prostate cancer,and increased in kidney cancer,colon cancer and thyroid papillary carcinoma.TTPE2 has shown its potential as a novel tumor therapeutic target and biomarker in various cancers.However,the expression condition and roles of TIPE2 in the development and progression of UCB are largely unknown.In this study,immunohistochemical staining（IHC）was used to detect TTPE2 expression in UCB tissues,and the clinical significance of TTPE2 protein expression in UCB patients was further evaluated by clinicapathological data analysis.Objective:This study aims to identify TIPE2 expression in UCB and its relationship to clinicopathological findings and prognosis.Materials and Methods:From July 2018 to October 2020,a total of 142 patients underwent radical cystectomy combined with pelvic lymph node dissection for bladder cancer in the Urology Department of the Second Affiliated Hospital of Anhui Medical University.According to the inclusion and exclusion criteria,110 patients were selected as the included subjects,and formalin-fixed paraffin-embedded tissue blocks of surgical specimens of BC from enrolled patients were collected from the Pathology Department of the Second Affiliated Hospital of Anhui Medical University.Eligible paraffin blocks from enrolled patients were selected and sequentially sectioned with 4μm thickness.The expression of TIPE2 in UCB tissues was detected by IHC,and clinicopathological and follow-up data of patients were collected for data analysis.Results:IHC results showed that TIPE2 was stained in various degrees in bladder cancer tissues,and expressed in both nucleus and cytoplasm.4.5%（5/110）showed negative expression,40.9%（45/110）showed low expression,and 54.5%（60/110）showed high expression.TIPE2 expression was negatively correlated with lymph node metastasis（P=0.004）and disease progression（P=0.021）.Survival curves were plotted to show that patients with high TIPE2 expression had a progression-free survival curve above those with negative/low TIPE2 expression（P=0.027）.In multivariate Cox proportional hazard regression analysis,TIPE2 was a protective factor for progression-free survival in bladder urothelial carcinoma（P=0.031）,pT stage（P=0.016）was a risk factor for progression-free survival,and age was a risk factor for overall survival（P=0.020）.Conclusions:TIPE2 was expressed in UCB tissues to varying degrees and was negatively correlated with lymph node metastasis and disease progression.Moreover,TTPE2 also played a role in differentiating tumor metastasis and prognosis.Low TTPE2 expression was associated with poor postoperative prognosis of UCB patients.Our results suggest that TTPE2 can be used as a potential biomarker to predict disease progression and prognosis in patients with UCB,providiig new ideas for the early diagnosis and treatment of UCB.In the future,we still need to improve the study through a large number of samples,and carry out the study of molecular mechanism of TTPE2 in UCB to clarify the possible role of TTPE2 as a potential target for UCB diagnosis and treatment. |
PDF Full Text Request